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RESEARCH ARTICLE
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Abstract
Objectives: Defining historical changes and outcomes in the use of gastrostomy in the management of Scottish MND
patients. Methods: The 1989–1998 and 2015–2016 Scottish national MND cohorts were used to examine the frequency,
timing, and survival related to gastrostomy. The cohorts were censored for survival analysis. Results: There were 261
cases, 119 (46%) from the new register (2015–2016) and 142 (54%) from the old register (1989–1999). Percutaneous
endoscopic gastrostomy (PEG) tubes were used exclusively in the old register vs. the new register where PEG (45%),
Radiologically inserted gastrostomy (RIG) (44%) and a small number of peroral image-guided gastrostomy (PIGG)
tubes (11%), p< 0.01 were used. Odds of 30-d mortality in the old register were 2.8 times that in the new register,
p< 0.01. Median survival time from gastrostomy was significantly higher in the new register, 2.7 months, p< 0.05.
Median survival time from onset was also higher in the new register but non-significant, 3.2 months, p¼ 0.30.
Multivariate analysis identified age at onset (hazard ratio [HR] 1.02 p¼0.01), time from onset to diagnosis (HR 0.74
p< 0.01), subtype of onset (HR 1.52 p¼0.01), with gastrostomy and Riluzole interacting as variables that predict risk of
death. Conclusions: Gastrostomy use has increased with techniques changing over time. It is safer and survival time has
increased post gastrostomy. Being older and diagnosed more quickly increases risk of death whilst taking Riluzole com-
bined with gastrostomy reduced risk of death. Survival from onset has not significantly changed in Scottish MND
patients having gastrostomy.
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Introduction
Motor neurone disease (MND) or more specific-
ally amyotrophic lateral sclerosis (ALS) is one of
the neurodegenerative disorders (1). What sets
MND apart is that it is a disorder whose impact is
rapidly profound with the median survival from
onset being less than three years in many health-
care systems across the world (2). Effective thera-
peutics have been difficult to develop despite a
multitude of trials over three decades (3). Only
one drug, Riluzole has been licensed (4) for this
disease until recently with a second drug
Edaravone gaining recent Food and Drug
Administration (FDA) approval (5). Much of the
management of MND is, and has necessarily
focused on symptom management. Significant
advances in this domain include the use of non-
invasive ventilation (NIV) (6), with an improved
survival and a positive impact on quality of life.
MND can present in around a third of patients
initially affecting speech and swallowing, so-called
bulbar onset patients. Many of these patients
develop early difficulties with swallowing which
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can impact on their quality of life and nutritional
status. It is not surprising that physicians and
healthcare professionals wish to help such individ-
uals by providing them with alternative routes by
which they can receive nutrition and hydration.
Chief among them is the gastrostomy and to a
lesser degree the nasogastric tube.
There has been much debate regarding the
when, who and how over gastrostomy insertion in
the MND/ALS population (7). Recent studies have
highlighted the potential deleterious nature of this
procedure (8). Indeed there was concern regarding
the role of gastrostomy in the Scottish MND popu-
lation in the early 2000s, where a one-month mor-
tality after gastrostomy of 25% in MND patients
was identified (9). There have been no randomized
trials of this intervention to guide clinicians and
such studies are unlikely to take place because of
ethical difficulties with regard to withholding
hydration and nutrition. In the light of the poten-
tial hazardous role of gastrostomy in MND patient
care, a study of artificial enteral nutrition using the
Scottish MND register was undertaken using a
national MND register. Comparisons over time
were made using historical data form the first
national MND register based here in Scotland
between 1989 and 1998 to identify if there had
been any changes in practice and outcome (10).
Methods
Study population
We used the recently relaunched Scottish MND
register and Scottish government statistics to com-
pare the frequency and timing of gastrostomy dur-
ing the two year period 2015–2016 with that of
the original Scottish MND register cohort
1989–1998. Strengthening the reporting of obser-
vational studies in epidemiology (STROBE)
reporting principles were adhered to in the prepar-
ation of the manuscript (11). Both cohorts were
censored to enable a comparison of survival. The
MND register in Scotland identifies patients from
multiple sources, including adult Neurologists,
MND care specialists and a platform that enables
self-identification via the Clinical Audit Research
Evaluation MND (CARE MND) website for
patients themselves. Ethical approvals were
obtained for the SMNDR/CARE-MND via the
Scotland A Research Ethics Committee. Access to
Information Services Division data was approved
by the Public Benefit and Privacy Panel for Health
and Social Care Scotland. To enhance the accur-
acy and quality of the data gastrostomy interven-
tions and mortality data were also captured by
examining Scottish Government national records
from the Information Service Division (ISD).
Using this capture-recapture technique ascertain-
ment in the Scottish MND register has been
identified at 99% (12). MND was defined by the
revised El Escorial criteria (13). Patients were
defined as having, Limb, Bulbar, Respiratory and
Behavioral/frontotemporal dementia subtypes at
onset. The incident cases diagnosed from the
beginning of 2015 to the end of 2016 were eval-
uated in this study with a censoring date of the 19
March 2018. Dates of disease onset, diagnosis and
gastrostomy were collected. Survival is from gas-
trostomy to either death or census date. Data on
potential confounders was collected for gender,
age, onset site, tube type, NIV, and Riluzole use.
Missing data
There were no missing data for covariates. We
excluded sixteen cases from the survival analysis
including nine patients with gastrostomy before
diagnosis (7 new and 2 old), six patients with
missing onset date (all old register) and one
patient with gastrostomy before onset and diagno-
sis (new register). These 16 cases were excluded
from the survival analysis but will be included
wherever possible to maximize data use.
Statistical analysis
Univariate analysis was performed using chi-square
test for categorical variables, t-test for comparison
of mean times and Mann–Whitney for comparison
of median times. Time from onset to gastrostomy,
survival time from onset and gastrostomy were all
heavily skewed with a number of outliers. For
these variables, medians are shown in Table 2 and
either non-parametric tests (Mann–Whitney) or
Kaplan–Meier with log-rank test were used to
compare the two registers. Correlation between
skewed variables was assessed by calculating
Pearson’s correlation on natural log transforms.
Survival analysis was performed using Cox regres-
sion with survival time (in months) from gastros-
tomy to either death or census date. Covariates
were “age at diagnosis (years)”, “time between
onset and diagnosis (in years)”, sex, “time between
diagnosis and gastrostomy (months)”, “site of
onset”, tube type and use of Riluzole, NIV status
and Register. Reference categories were “female”
for gender, “bulbar” for site of onset, “PEG and
no use of Riluzole” for tube type and use of
Riluzole, no NIV and “old register” for register.
The old register covered a longer time period
and this may affect the survival analysis. To adjust
for this any patients in the old register with sur-
vival longer than the longest in the new register
(825 d) were reset as alive and censored at 825 d.
This affected nine patients, five of whom had died;
this is referred to as the “adjusted old register”.
Statistical analysis was performed using SPSS ver-
sion 24 (SPSS Inc., Chicago, IL) and R using R
commander (Vienna, Austria) (14).
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Table 1. Sample characteristics by register.
Overall (n5 261)
New register
(2015–16) (n5 119)
Old register
(1989–98) (n5 142) p; OR (95% CI)
Gender (n, % male) 128 (49%) 74 (62%) 54 (38%) p<0.01; OR 2.7
(1.6, 4.4)
Onset (n, % bulbar) 151 (60%) 64 (57%) 87 (62%) p¼0.46NS
NIV (n, %) 49 (19%) 49 (41%) 0 p<0.01
Mortality (n, %) 233 (89%) 97 (82%) 136 (96%) p<0.01; OR 0.20
(0.08, 0.50)
Adjusteda mortality (n, %) 233 (89%) 97 (82%) 131 (92%) p<0.01; OR 0.37
(0.17, 0.80)
30-d mortality rate (n, %) 46 (18%) 12 (10%) 34 (25%) p<0.01; OR 0.36
(0.18, 0.73)
Tube type & use of Riluzole
PEG & no Riluzole 148 (57%) 23 (19%) 125 (88%) p<0.01
PEG & Riluzole 48 (18%) 31 (26%) 17 (12%)
RIG & no Riluzole 21 (8%) 21 (18%) 0
RIG & Riluzole 31 (12%) 31 (26%) 0
PIGG & no Riluzole 4 (2%) 4 (3%) 0
PIGG & Riluzole 9 (3%) 9 (8%) 0
Gastrostomy n¼111 n¼140
<3 months from diagnosis 57 (23%) 20 (18%) 37 (26%) p<0.05
3–6 months from
diagnosis
52 (21%) 28 (25%) 24 (17%)
6–12 months from
diagnosis
61 (24%) 34 (31%) 27 (19%)
Over 12 months
from diagnosis
81 (32%) 29 (26%) 52 (37%)
Chronological data
by register
Overall New register Old register Difference, p
Mean (±SD) age at
Onset (years)
63.5±12.0 62.6±12.7 64.3± 11.4 1.7; p¼0.26NS
Mean (±SD) age at
Diagnosis (years)
64.7±12.0 63.6±12.5 65.6± 11.5 1.9; p¼0.19NS
Mean (±SD) age at
gastrostomy (years)
65.6±11.7 64.2±12.3 66.8± 11.0 2.6; p¼0.07NS
Median (±IQR) time
onset to diagnosis
(months)
9.7± 8 10±7.6 9.0± 4.0 1.0; p¼0.09NS
Median (±IQR) time
onset to gastrostomy
(months)
17.7±15.1 16.8±13.9 18.4± 16.3 1.6; p¼0.64NS
Median survival time from
onset (months)b
26.6±2.3 28.4±3.7 25.2± 3.9 3.2, p¼0.30NS
Median (±IQR) survival
time from gastrostomy
(months)b
7.2±1.1 8.1±1.7 5.4± 1.8 2.7; p¼0.04
p is from chi-square test, OR: odds ratio. p from two-sample t-test for means and Mann–Whitney tests for medians and log-rank
test for survival.
aOn adjusted old register. bResults are the same using adjusted old register.
Table 2. HR (95% CI) for stepwise Cox regression of survival time from gastrostomy.
p HR (95% CI)
Age at onset (years) 0.01 1.02 (1.01, 1.03)
Time (years) onset to diagnosis <0.01 0.75 (0.62, 0.90)
Subtype onset site (spinal) 0.01 1.52 (1.10, 2.11)
Gastrostomy (reference PEG with no Riluzole) 0.049
PEG tube & Riluzole 0.036 0.66 (0.45, 0.97)
RIG tube (no Riluzole) 0.081 0.61 (0.35, 1.06)
RIG tube & Riluzole 0.042 0.63 (0.41, 0.98)
Cox & Snell R squared ¼ 0.12.
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Results
Sample characteristics
As can be seen from Table 1 there were a total of
261 cases with 119 (46%) from the new register
(2015–2016) and 142 (54%) from the old register
(1989–1998). There were significant differences in
the sex distribution between the two registers. The
majority of cases in the new register (62%) were
male but they formed the minority in the old regis-
ter (38%), the change was statistically significant
p<0.01; odds ratio 2.7 (confidence interval [CI],
1.6–4.4). In both registers, patients who had gas-
trostomy tubes inserted were predominantly bulbar
in onset (60%) with no significant difference
between the two groups. There were significant
changes in the types of gastrostomy tubes used,
the use of Riluzole and NIV. No patients in the
old register received NIV but this had been used
in 41% of patients in the new register by the time
of censorship. Mean age at onset and gastrostomy
were lower in the new register although the differ-
ence only approached significance for age at gas-
trostomy. Median time between onset and
gastrostomy was lower in the new register but the
difference was not significant.
Survival and mortality
Median time between onset and death and from
gastrostomy to death was higher in the new regis-
ter, however, only survival from gastrostomy was
statistically significant (Kaplan–Meier analysis, log-
rank test p¼0.04, Figure 1). There was a statistic-
ally significant difference in both overall and 30-d
mortality, odds of both overall and 30-d mortality
in the old register was around 2.8 times that in the
new register. The distribution of time from diagno-
sis to gastrostomy between registers was different.
In the new register, there were roughly equal num-
bers “<3 mths”, “3–6 mths”, “6–12 mths”, and
“>12 mths” from diagnosis. In the old register,
there were more in the two extreme categories,
“<3 mths” and “>12 mths”. This was not how-
ever linked to greater 30-d mortality, with the
mortality rate of 25% consistent across the time
categories (Table 1). In the old register, there was
a weak positive correlation between time from
onset to diagnosis and time from diagnosis to gas-
trostomy (r¼ 0.22, p¼0.01). Those in whom the
disease progression was slower tended to wait lon-
ger for gastrostomy. There was no such correlation
in the new register (r¼ 0.07, p¼ 0.49) the timing
of gastrostomy was not related to disease
progression.
Cox regression model
A backward stepwise Cox regression was run with
survival time (in months) from gastrostomy to
either death or census date and all other factors as
covariates. There were 239 cases in the model
with 22 (8%) missing. There were 214 (90%)
deaths. The model fit was poor (R squared =
0.12). In the final model age at onset, time
between onset and diagnosis, subtype, Riluzole
use, and gastrostomy tube were significant predic-
tors (Table 2). The use of Riluzole and type of
tube differed significantly between the two registers
(Table 1). Both RIG tubes and Riluzole were
more widely used in the new register. The findings
were not materially different when using the
adjusted old register. There is a potential bias in
the use of Riluzole in that it may not be given to
individuals who were deteriorating quickly.
However, the median time from onset to diagnosis
was similar for those with and without Riluzole
Figure 1. Kaplan–Meier survival analysis of old and new registers post gastrostomy, log-rank test p¼0.04.
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(median± IQR; no Riluzole 9.99±9.07 months;
Riluzole 9.25±7.18 months; p¼ 0.84).
Discussion
Gastrostomy is widely used to improve nutrition
and hydration in people with MND, its efficacy,
however, has not been evaluated in a clinical trial.
Our earlier study highlighted the potentially dele-
terious nature of the procedure because at a time
when the intervention was being introduced from
1989 to 1998 the 30-d mortality was 25%. Since
then patient selection, treatments, and operative
techniques have changed. With the relaunch the
Scottish MND register we have been able to com-
pare the frequency, timing, and survival in the new
register with historical data.
We have collected information on a national
basis with a high level of case ascertainment. This
has limited but not eliminated bias by recall, case
selection, or that produced by a particular center
and its procedures. For example a center may only
have access to one particular gastrostomy insertion
technique. In addition a unique historical perspec-
tive was possible given access to original data from
one of the first national MND registers in the
world, based in Scotland between 1989 and 1998
(12,15). However, there are limitations in this
study, with possible ascertainment bias produced
by retrospective data collection. It is not a
randomized study so causation cannot be inferred
only association. Bias due to lack of inclusion will
be reduced by the use of a national register with
near complete case identification. The time period
for follow up after the 2015–2016 cohort was dif-
ferent from the 1989–1998 cohort. This was
adjusted as part of the statistical approach. No
nutritional data such as body mass index (BMI)
were collected in the original register that limited
its use as a variable in the analysis. There is evi-
dence that weight loss of 10% or more prior to
gastrostomy can predict a poorer outcome (16).
Quality of life data on the impact of gastrostomy
was not collected in the original register and this is
an additional limitation of this work. In the ori-
ginal register, data on cognition was not collected
nor was their identification of the presence or
absence of multidisciplinary care. Multidisciplinary
care has been identified to improve survival in
MND patients (17). It is increasingly recognized
that patients with MND can have significant cog-
nitive deficits and this is associated with a poorer
prognosis (18,19). One further limitation of this
work relates to complications post procedure.
These were not examined and the cause of death
in those dying within the 30-d period post gastros-
tomy was not identified either in the old register or
the new register.
There are significant differences between the
two registers with regard to sex, use of Riluzole,
use of NIV, types of gastrostomy, and 30-d mor-
tality. Some of the differences reflect evolution of
clinical practice, for example Riluzole was not
widely available for patients with MND in
Scotland during the time of the old register and
NIV was not yet identified as an effective treat-
ment for MND patients until 2006. Radiological
insertion of gastrostomy is also a more recent
development. The reason for the change in sex dis-
tribution is unknown. It was of interest to examine
how these new variables and the passage of time
may have impacted on the use and outcomes of
gastrostomy in the Scottish MND population.
We have observed a significant increase in the
number of gastrostomies in our population, 119 in
a two year period vs. 142 from 1989 to 1998. It is
safer now with a lower 30-d mortality of 10%.
This is higher than the PROGAS study figure of
4% (16), however, our ascertainment technique
was population-based so was less likely to be sub-
ject to inclusion bias. Reassuringly, the 10% 30-d
mortality is similar to that reported in a recent
meta-analysis of gastrostomy in MND (20). This
analysis did incorporate studies that were relatively
small in number and related to historical practice.
More men are having the procedure performed 62
vs. 38% and the median survival from gastrostomy
was significantly increased (8.1 vs. 5.4 months,
(2.7, p< 0.05)) while overall survival from onset
was also increased but not significantly (28.4 vs.
25.2 months (3.2, p¼ 0.30, NS)). The cause of
these changes is likely to be complex.
There are clearly increasing number of gastro-
stomies occurring in this patient population.
Decision making surrounding gastrostomy is com-
plex (21). More people could be undergoing gas-
trostomy because of the increasing amounts of
readily accessible information via social media and
the internet for example https://mytube.mymnd.
org.uk/. There may also be an increasing availabil-
ity of the procedure. Radiological Insertion of
Gastrostomy is now more routine and can be per-
formed on more advanced patients with respiratory
compromise (22). Other factors that may be con-
tributory could include a more interventional
approach to palliative care and an increasing
involvement of patients in decision making with
regard to their care.
Many factors are likely to contribute to risk
when it comes to survival after a gastrostomy. It is
interesting to observe that in the new register,
there were fewer gastrostomies being performed
within three months of diagnosis or after 12
months from diagnosis. Performing gastrostomies
at the two extremes my select out patients who are
deteriorating faster and who are at the end stages
of their condition and could contribute to the
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differences seen in the study. The results of the
multivariate analysis indicate that Riluzole and gas-
trostomy interact and are significant variables that
are contributing to the observed change in survival
after gastrostomy in the new register. When these
are controlled for, the variable of “register” loses
its significance in the multivariate analysis.
Radiological insertion of gastrostomy was not per-
formed during the time of the old register. It can
be conducted with the use of less sedation. This
may contribute to an improved safety profile of the
technique in patients who have respiratory com-
promise. RIG without Riluzole, when compared to
PEG without Riluzole, was not significant suggest-
ing an important contribution of Riluzole in the
interaction. Riluzole was given infrequently in the
old register. There is evidence that it slows disease
in randomized trials and reduces risk of death in
disease registers (23). There was no suggestion
that Riluzole use was skewed to individuals who
were progressing less quickly. The PROGAS study
did identify that RIG tubes were associated with
more complications post procedure but did not
identify an increased mortality pattern with their
use compared with PEG tubes. The PROGAS
study, however, did not collect data on Riluzole
and it was not factored into the analysis.
It is interesting to note that the use of NIV did
not appear to be a significant variable with regard
to survival after a gastrostomy in the Cox model.
It should be noted that the timing of NIV was not
specified in this analysis (that is before or after the
procedure). The timing of the introduction of NIV
may reduce risk of sedation during interventional
procedures, such as gastrostomy. NIV use in
patients with bulbar onset disease can be challeng-
ing and its benefit is less in terms of its impact on
survival (6). This may be one factor that contrib-
utes to the lack of effect on survival from diagnosis
between the two cohorts despite the introduction
of NIV over time (24). This is an area that
requires further study.
Age at diagnosis and speed of diagnosis were
contributory variables that influence survival after
gastrostomy. They have been observed by others
in MND registers as variables which predict prog-
nosis (25). Every year of age at onset increased
HR by 2%, which should be noted when consider-
ing gastrostomy in the very old (50 years HR 2 vs.
85 years HR 2.7). Every year between onset and
diagnosis reduced HR by 26% while spinal onset
increased HR by 53%. The increased hazard asso-
ciated with spinal onset is likely to reflect the ten-
dency to perform gastrostomy in spinal onset
patients later on in the disease course compared to
bulbar onset patients. None of the other variables
were significant, in particular time from diagnosis
to gastrostomy made no difference to survival in
the populations under study.
Conclusions
These observations may help guide decision mak-
ing with regard to gastrostomy in MND patients.
This study is not designed to advocate one particu-
lar approach but provides a historical analysis of
gastrostomy in Scottish MND patients. It supports
an individualized and holistic approach rather than
a time-pressured or prophylactic approach to the
use of gastrostomy in patients with MND. The use
of Riluzole combined with gastrostomy in the
management of MND patients is supported by this
research. Despite the advances of NIV and
Riluzole in the intervening 20 years it was disap-
pointing not to see a significant improvement in
survival from onset. This may reflect the predom-
inant bulbar onset pattern in the population that
was studied (60%) double that seen in an unse-
lected MND population. The difference in survival
between the two registers form gastrostomy was
small and its impact on survival from onset was
lost in the variation over the longer time period.
This variation reflects a complex reality involving a
large number of variables that can affect MND
patient’s survival many of which were not captured
in this work. The lack of significant change in sur-
vival from onset over a 20-year interval emphasizes
the importance of developing new effective thera-
peutics to treat this devastating condition. Given
the limited impact on survival, it will be important
for future work to define the impact of gastrostomy
on the quality of life of MND patients who have
this procedure performed. One approach would be
to prospectively collect data on survival and quality
of life in those who have and who do not have gas-
trostomies inserted. An alternative approach would
be to perform a randomized trial on those where
the decision to intervene is not clear cut and col-
lect such data.
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